No trading catalyst is present in this filing. The proxy statement is a standard disclosure for an upcoming shareholder meeting. Traders should monitor for any subsequent filings related to voting results or changes in corporate strategy, but this document alone does not signal a material event.
EBS drugs
EBS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $8.62entry
- T+1 · 7mo ago +2.20%α +0.99% · $8.81
- T+5 · 7mo ago −6.15%α −7.13% · $8.09
- T+20 · 6mo ago −3.36%α −9.18% · $8.33
- T+60 · 4mo ago −7.08%α −14.12% · $8.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Emergent BioSolutions Inc. (EBS) filed its definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockholders, scheduled for April 29, 2026. The filing outlines proposals for shareholder voting, including director elections and executive compensation, as part of routine corporate governance. No material changes or activist challenges are indicated.
Key Financial Metrics
Key Facts
- Filing is a routine proxy statement (DEFA14A) for the 2026 Annual Meeting of Stockholders
- Meeting date set for April 29, 2026
- No indication of dissident or activist involvement
- Proposals include standard items: election of directors, executive compensation, and shareholder proposals
Financial Impact
No immediate financial impact
Risk Factors
- Low risk of unexpected shareholder proposals or voting outcomes given the routine nature of the filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-158138 |
| Document: 0001193125-26-158138-index-headers.html | 0001193125-26-158138 |
| Document: 0001193125-26-158138-index.html | 0001193125-26-158138 |
| Document: 0001193125-26-158138.txt | 0001193125-26-158138 |
Track record
23 reports on EBS
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers